153 related articles for article (PubMed ID: 3201181)
21. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.
Perry PJ; Miller DD; Arndt SV; Smith DA; Holman TL
J Clin Psychopharmacol; 1993 Feb; 13(1):46-51. PubMed ID: 8486817
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
[TBL] [Abstract][Full Text] [Related]
23. Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid.
Straw GM; Bigelow LB; Kirch DG
J Clin Psychopharmacol; 1989 Apr; 9(2):130-2. PubMed ID: 2566628
[TBL] [Abstract][Full Text] [Related]
24. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
[TBL] [Abstract][Full Text] [Related]
25. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.
Smith RC; Baumgartner R; Shvartsburd A; Ravichandran GK; Vroulis G; Mauldin M
Psychopharmacology (Berl); 1985; 85(4):449-55. PubMed ID: 2862652
[TBL] [Abstract][Full Text] [Related]
27. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients.
Chang WH; Chen TY; Lee CF; Hu WH; Yeh EK
Biol Psychiatry; 1987 Nov; 22(11):1406-8. PubMed ID: 3663790
[No Abstract] [Full Text] [Related]
28. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
[TBL] [Abstract][Full Text] [Related]
29. Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens.
Donlon PT; Hopkin JT; Tupin JP; Wicks JJ; Wahba M; Meadow A
Arch Gen Psychiatry; 1980 Jun; 37(6):691-5. PubMed ID: 7387340
[TBL] [Abstract][Full Text] [Related]
30. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.
Balant-Gorgia AE; Eisele R; Balant L; Garrone G
Eur Arch Psychiatry Neurol Sci; 1984; 234(1):1-4. PubMed ID: 6489392
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.
Yasui-Furukori N; Kondo T; Ishida M; Furukori H; Suzuki A; Kaneko S; Inoue M; Otani K
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):53-7. PubMed ID: 11853119
[TBL] [Abstract][Full Text] [Related]
32. Cognitive changes in acute schizophrenia with brief neuroleptic treatment.
Wahba M; Donlon PT; Meadow A
Am J Psychiatry; 1981 Oct; 138(10):1307-10. PubMed ID: 7294185
[TBL] [Abstract][Full Text] [Related]
33. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
[TBL] [Abstract][Full Text] [Related]
34. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
[TBL] [Abstract][Full Text] [Related]
35. Haloperidol plasma levels and dose optimization.
Coryell W; Miller DD; Perry PJ
Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338
[TBL] [Abstract][Full Text] [Related]
36. Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine.
Minami H; Nakahara T; Miyahara A; Nakane Y
Psychiatry Clin Neurosci; 1997 Aug; 51(4):217-22. PubMed ID: 9316167
[TBL] [Abstract][Full Text] [Related]
37. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
[TBL] [Abstract][Full Text] [Related]
38. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
Santos JL; Ramos JA; Prieto P; Almoguera I; Vazquez C; Rubio ME; Cabranes JA
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):917-25. PubMed ID: 2813809
[TBL] [Abstract][Full Text] [Related]
39. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement.
Bartkó G; Herczeg I; Békésy M
J Clin Psychiatry; 1987 Sep; 48(9):363-5. PubMed ID: 3624207
[TBL] [Abstract][Full Text] [Related]
40. Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.
Chang WH; Chen TY; Lin SK; Lung FW; Lin WL; Hu WH; Yeh EK
Biol Psychiatry; 1990 Mar; 27(5):510-8. PubMed ID: 2310806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
